Showing results (81-90 of 105) with videos related to
Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) studyE Aranda, E Díaz-Rubio, A Cervantes, et al.Occupational and Environmental Medicine|March 25, 2006
Assessment of lifetime exposure to trihalomethanes through different routesC M Villanueva, K P Cantor, J O Grimalt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancerF Cardenal, M P López-Cabrerizo, A Antón, et al.BMC Cancer|June 5, 2016
Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic modelsE López de Maturana, A Picornell, A Masson-Lecomte, et al.Occupational and Environmental Medicine|November 30, 2007
Work in the textile industry in Spain and bladder cancerC Serra, M Kogevinas, D T Silverman, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 5, 2017
Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE studyR López López, C Camps Herrero, P Khosravi-Shahi, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2018
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)C Camps Herrero, J J Reina Zoilo, D Monge Martín, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2011
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancerN Starling, F Vázquez-Mazón, D Cunningham, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 14, 2014
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologistsC Camps-Herrero, L Paz-Ares, M Codes, et al.Pageof 11